Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 3, 2002, Pages 161-169

  Jurado, Manuel ^a   Deeg, H Joachim ^a   Storer, Barry ^a   Anasetti, Claudio ^a   Anderson, Jeanne E ^a   Bryant, Eileen ^a   Chauncey, Thomas ^a   Doney, Kris ^a   Flowers, Mary E D ^a   Hansen, John ^a   Martin, Paul J ^a   Nash, Richard A ^a   Petersdorf, Effie ^a   Radich, Jerry ^a   Sale, George ^a   Sandmaier, Brenda M ^a   Storb, Rainer ^a   Wade, James ^a   Witherspoon, Robert ^a   Appelbaum, Frederick R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Advanced MDS; Conditioning regimen; Nonrelapse mortality; Relapse

Indexed keywords

ACICLOVIR; ANTHRACYCLINE; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUCONAZOLE; GANCICLOVIR; GROWTH FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; TACROLIMUS; TOPOTECAN; VITAMIN;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLAST TRANSFORMATION; CAUSE OF DEATH; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DONOR; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RECURRENCE RISK; REFRACTORY ANEMIA; RELAPSE; RELATIVE; SCORING SYSTEM; SEROLOGY; SURVIVAL RATE; WHOLE BODY RADIATION; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL;

ADOLESCENT; ADULT; BUSULFAN; CAUSE OF DEATH; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 0036205613     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm11939606     Document Type: Article

References (49)

1. Prognostic factors in myelodysplastic syndromes
2. International scoring system for evaluating prognosis in myelodysplastic syndromes
3. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation
4. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
5. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
6. Phase II study of busulfan (BU) and total body irradiation (TBI) as a novel preparative regimen in allogenic marrow transplantation (BMT) for advanced myelodysplastic syndrome
7. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
8. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: A report on behalf of the Chronic Leukaemia Working Party of the European Transplantation (EBMT)
9. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients: Report of the French Society of Bone Marrow Transplantation
10. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
11. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: A phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors
12. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients Societe Francaise de Greffe de Moelle
13. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome: Chronic Leukemia Group for Blood and Marrow Transplantation
14. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey: European Blood and Marrow Transplantation Group
15. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia
16. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
17. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation
18. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
19. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
20. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
21. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial
22. Acute graft-versus-host disease
23. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease
24. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors
25. The biologic significance of rare peripheral blasts after hematopoietic cell transplantation is predicted by multidimensional flow cytometry
26. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers
27. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry
28. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation
29. Nonparametric estimation from incomplete observations
30. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
31. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
32. Emerging role of topoisomerase I inhibitors in the therapy of high risk MDS and CMML
33. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia
34. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
35. Ineffective in vivo prophylaxis of graft-versus-host disease due to conditioning induced organ toxicity
36. Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
37. A role for tumor necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
38. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction
39. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
40. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation
41. Methods for assessment of graft-versus-host disease
42. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma
43. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program
44. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia
45. Cytomegalovirus infection after BMT
46. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
47. A three center European quality control study of the use of PCR for the detection of CMV DNA in blood
48. Pathophysiologic mechanisms of acute graft-vs.-host disease
49. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation